Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies that arise from secretory endocrine cells of the gastroenteropancreatic system. Clinical outcomes have improved for patients with GEP-NETs due to the development and recent FDA approval of (177)Lutetium DOTATATE. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Vivian, Taparra, Kekoa, Fisher, George, Aparici, Carina, Soltys, Scott G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Radiation Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577096/
https://www.ncbi.nlm.nih.gov/pubmed/37849592
http://dx.doi.org/10.7759/cureus.45327
Descripción
Sumario:Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies that arise from secretory endocrine cells of the gastroenteropancreatic system. Clinical outcomes have improved for patients with GEP-NETs due to the development and recent FDA approval of (177)Lutetium DOTATATE. However, the response of brain metastases from GEP-NETs from (177)Lutetium DOTATATE is unreported. We present the case of an 81-year-old man with low-grade small bowel GEP-NET with liver and brain metastases treated with a total of six cycles of (177)Lutetium DOTATATE. With over three years of follow-up from his initial treatment, his brain metastases have had complete or partial responses, with no need for brain radiotherapy or radiosurgery.

Ejemplares similares